Business
Paypal uncertainty
(CSA Archive/Getty Images)

Citing uncertainty, PayPal leaves full-year guidance unchanged

The parent company of Venmo stressed that its focus on profitability over growth will help it weather economic turbulence.

Venmo parent PayPal is up slightly after posting mixed earnings and emphasizing that its focus on profitability over growth will help it weather growing uncertainty for the economy.

The company reported first-quarter earnings per share of $1.33, better than the $1.16 Wall Street had expected. But sales were a slightly soft $7.79 billion, compared to the $7.85 billion that analysts had penciled in.

PayPal didn’t raise its full-year forecast for earnings, either. CEO Alex Chriss explained:

“We had a great start to the year and expect a solid second quarter, which would result in the first half coming in above our prior expectations. However, given it is early in the year and because of the current level of macro uncertainty, we are maintaining our guidance for the full year at this time.”

Investors seem more or less comfortable with that. Shares rebounded after a premarket slump, perhaps soothed by the company’s disclosure in a conference call that less than 2% of its “total payments volume” — the company’s preferred earnings metric — comes from China. That seemed to have assuaged worries that the end of the de minimis tax exemption that the Trump administration is killing off on May 2 could pose a risk to the company, as it has for Chinese companies like Shein and Temu.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.